Integrated evaluation of pharmacokinetics and pharmacogenomics of sunitinib and pazopanib in patients with metastatic renal carcinoma
Year: 2026
Type: article
Abstract: Aim Sunitinib and pazopanib are anti‐angiogenic tyrosine kinase inhibitors (TKIs) used for metastatic renal cancer, with substantial interindividual variability in drug response. This study aimed to explore factors explaining this variability. Methods Pharmacokinetics (PK) and pharmacogenomics (PG) data from 47 patients enrolled in the SUP‐R clinical trial (NCT02555748) were analysed retrospectively (32 treated with sunitinib, 15 with pazopanib). Plasma concentrations measured during the first two treatment cycles were analysed using a non‐linear mixed effects model. Exploratory analyses of factors influencing drug exposure, toxicity and efficacy were conducted, including a PG investigation of drug disposition, and target genes and baseline circulating microRNA levels. No correction for multiple comparisons was applied. Results The PK models adequately described plasma concentration over time in the cohort. Patients experiencing severe toxicity (≥ Grade 3, CTCAE) showed reduced apparent sunitinib clearance (median 24.3 L/h [11.1–45.7] vs . 32.4 L/h [16.6–90.6], p = 0.006). Responders were more exposed to sunitinib and active metabolite SU12662 (observed C trough,ss = 140.1 ng/mL [43.2–209.5] vs . 89.5 ng/mL [4.3–230.7], p = 0.036); similar trends were observed with pazopanib, though limited events (3 responders/10 evaluable) precluded definitive interpretation. Carriers of at least one variant ABCB1 c.1199G>A allele were more likely to respond to TKI treatment (odd‐ratio = 10.8, 95% confidence interval [1.7–69.9], p = 0.012). Conclusion This study assessed the exposure‐response relationships of both drugs and identified potential factors to consider in case of toxicity or treatment failure.
DOI: 10.1002/bcp.70918
Authors: Maud Maillard, Matthieu Gracia, Bastien Cabarrou, Félicien Le Louedec, Christelle Moreau, Mathieu Landry, Aurélie Brice, Thierry Lafont, Deniz Ozdin, Ben Allal, Diego Tosi, Gwenaelle Gravis, Guilhem Roubaud, Frédéric Thuillier, Helen Boyle, Florent Puisset, Mélanie White‐Koning, Anne Pradines, Etienne Chatelut, Loïc Mourey, Fabienne Thomas
Institutions: Inserm, Centre de Recherches en Cancérologie de Toulouse, Institut universitaire du cancer de Toulouse Oncopole, Institut Claudius Regaud, Université de Montréal, Institut Regional du Cancer de Montpellier, Centre National de la Recherche Scientifique, Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Institut Bergonié, Centre Hospitalier Universitaire de Limoges, Centre Léon Bérard
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,780
OpenAlex ID: W7233877390
